Argus downgraded Charles River to Hold from Buy. The company continues to face headwinds to revenue growth due to cautious spending by the biotech industry, the analyst tells investors in a research note. The firm cut estimates and says Charles River shares have been in a bearish pattern of lower highs and lower lows since March.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- Charles River initiated with an Equal Weight at Barclays
- Charles River announces strategic collaboration with Gates Institute
- ‘The CRO Sector Looks Appealing,’ Says Goldman Sachs — Here Are 2 Stocks to Consider
- Charles River, Captain T Cell in plasmid DNA-Viral Vector alliance
- Charles River in collaboration with MatTek awarded $1.3M grant from FCRI